Physician preferences for non-metastatic castration-resistant prostate cancer treatment

BACKGROUND: Recent approvals of second-generation androgen receptor inhibitors (SGARIs) have changed the treatment landscape for non-metastatic castration-resistant prostate cancer (nmCRPC). These SGARIs have similar efficacy but differ in safety profiles. We used a discrete choice experiment to exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Srinivas, Sandy, Mohamed, Ateesha F., Appukkuttan, Sreevalsa, Botteman, Marc, Ng, Xinyi, Joshi, Namita, Horodniceanu, Erica, Waldeck, A. Reginald, Simmons, Stacey J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310549/
https://www.ncbi.nlm.nih.gov/pubmed/32571276
http://dx.doi.org/10.1186/s12894-020-00631-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310549/
https://www.ncbi.nlm.nih.gov/pubmed/32571276
http://dx.doi.org/10.1186/s12894-020-00631-4

Ejemplares similares